biogenic amine

(redirected from Biogenic amines)
Also found in: Thesaurus, Medical, Encyclopedia.

biogenic amine

n.
Any of a group of naturally occurring, biologically active amines, many of which are neurotransmitters, including norepinephrine, dopamine, and serotonin.
References in periodicals archive ?
Biogenic amines can provoke allergic reactions in some people, leading to nausea, headaches and other symptoms, and alcohol amplifies the effects.
The present study evaluated the changes of sensorial paremeters, microbiological examinations (aerobic mesophiles, psychrotrophs and histamine-producers bacteria) and formation of biogenic amines in three lots: I (june), II (july) and III (november) of sardine (Sardinella aurita).
Biogenic amines function as neurotransmitters in a wide array of animals (Werman, 1966; Gerschenfeld, 1973; Fingerman, 1985).
These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, without limitation, statements regarding the company's clinical development plans for its proprietary compounds, the company's research programs and the license arrangement with BMS concerning the company's biogenic amines program.
Multidetection semiquantitative method for determining biogenic amines in foods.
However, sucrose and detergents, biogenic amines, chlorpromazine, penicillins, vitamin C, paracetamol, hydrogen peroxides, or any compound that can reduce [Cu.
Biogenic amines in the ink were detected electrochemically with an ESA Coulochem (Model 5100A; 5021 conditioning cell; 5011 analytical cell) in the reductive mode (Gomez-Nino et al.
Also, the resulting wine is less likely to contain biogenic amines, which are produced by the bacterial malolactic fermentation and which can have negative health effects.
Four of these candidates have moved into Phase I clinical testing: two compounds from AMRI's biogenic amines program being studied for the treatment of central nervous system (CNS) disorders by Bristol-Myers Squibb Company (NYSE: BMY) as part of a licensing arrangement; one from AMRI's independent tubulin inhibitor program, currently in Phase I testing in cancer patients; and most recently, one from AMRI's proprietary MCH1 program for the treatment of obesity entered into Phase I testing as of July 2010.
Previously announced Phase I study programs include two compounds from AMRI's biogenic amines program being studied for the treatment of central nervous system (CNS) disorders as part of a licensing agreement with Bristol-Myers Squibb Company (NYSE: BMY), and one from AMRI's proprietary anti cancer program.
The Aestus proprietary technology advances the search for viable products to treat psychiatric disorders in a manner different from modifying the effect of the so called biogenic amines, the traditional therapeutic approach for these disorders.
Issuing from the above said, we put forward a goal of studying degree of maturity of food-seeking and defensive tasks as well as dynamics of free dicarboxylic amino acids, GABA and biogenic amines in the brain of sturgeon juveniles, bred by different methods, and of wild juveniles, caught in the river, depending on the dwelling conditions and age.